Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
US Market
Holding NMRA?
Track your performance easily

Neumora Therapeutics, Inc. (NMRA) Income Statement

135 Followers

Neumora Therapeutics, Inc. Income Statement

Last quarter (Q2 2024), Neumora Therapeutics, Inc.'s total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Neumora Therapeutics, Inc.'s net income was £-58.70M. See Neumora Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22
Total Revenue
---
Cost of Revenue
---
Gross Profit
---
Operating Expense
£ 180.76M£ 252.10M£ 135.87M
Operating Income
£ -180.76M£ -252.10M£ -135.87M
Net Non Operating Interest Income Expense
£ 15.47M£ 16.61M£ 4.56M
Other Income Expense
£ 37.00K£ 170.00K£ -405.00K
Pretax Income
£ -165.32M£ -235.66M£ -130.90M
Tax Provision
£ 125.00K£ 268.00K-
Earnings From Equity Interest Net Of Tax
---
Net Income Common Stockholders
£ -165.45M£ -235.93M£ -130.90M
Basic EPS
£ -1.85£ -3.63£ -4.81
Diluted EPS
£ -1.85£ -3.63£ -4.81
Basic Average Shares
£ 363.62M£ 65.02M£ 27.21M
Diluted Average Shares
£ 363.62M£ 65.02M£ 27.21M
Dividend Per Share
---
Total Operating Income As Reported
---
Reported Normalized Basic E P S
---
Reported Normalized Diluted E P S
---
Rent Expense Supplemental
---
Total Expenses
£ 180.76M£ 252.10M£ 135.87M
Net Income From Continuing And Discontinued Operation
£ -165.45M£ -235.93M£ -130.90M
Normalized Income
£ -57.99M--
Interest Expense
---
EBIT
£ -123.90M£ -235.66M-
EBITDA
£ -123.58M£ -238.70M-
Currency in GBP

Neumora Therapeutics, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis